Cargando…

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

BACKGROUND: Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vale, Claire L, Burdett, Sarah, Rydzewska, Larysa H M, Albiges, Laurence, Clarke, Noel W, Fisher, David, Fizazi, Karim, Gravis, Gwenaelle, James, Nicholas D, Mason, Malcolm D, Parmar, Mahesh K B, Sweeney, Christopher J, Sydes, Matthew R, Tombal, Bertrand, Tierney, Jayne F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737894/ https://www.ncbi.nlm.nih.gov/pubmed/26718929 http://dx.doi.org/10.1016/S1470-2045(15)00489-1

Ejemplares similares

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
por: Rydzewska, Larysa H.M., et al.
Publicado: (2017)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
por: Vale, C L, et al.
Publicado: (2018)

A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials
por: Tierney, Jayne F., et al.
Publicado: (2021)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

Assessing and improving the reliability of meta-analyses of hazard ratios derived from published time-to-event data
por: Tierney, Jayne, et al.
Publicado: (2013)

Sharing individual participant data: through a systematic reviewer lens
por: Rydzewska, Larysa H. M., et al.
Publicado: (2022)

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials()
por: Vale, Claire L., et al.
Publicado: (2015)

Practical methods for incorporating summary time-to-event data into meta-analysis
por: Tierney, Jayne F, et al.
Publicado: (2007)

Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study
por: Tierney, Jayne F., et al.
Publicado: (2020)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer
por: South, Annabelle, et al.
Publicado: (2016)

Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate
por: Ishibashi, Masaya, et al.
Publicado: (2012)

Systemic treatment for metastatic prostate cancer
por: Gravis, Gwenaelle
Publicado: (2019)

Analysis of survival data from trials with non-proportional hazards: an empirical comparison of methods
por: Royston, Patrick, et al.
Publicado: (2013)

Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
por: Fisher, David J., et al.
Publicado: (2022)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

The need for a cultural shift from two-arm to multi-arm RCTS
por: Sydes, Matthew R, et al.
Publicado: (2013)

A framework for the design and analysis of phase III randomised trials in uncommon diseases
por: Parmar, Mahesh, et al.
Publicado: (2015)

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2021)

Measuring impact of systematic reviews using individual participant data: evidence from clinical guidelines
por: Vale, Claire, et al.
Publicado: (2013)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

How individual participant data meta-analyses have influenced trial design, conduct, and analysis
por: Tierney, Jayne F., et al.
Publicado: (2015)

Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics
por: Bowden, Jack, et al.
Publicado: (2011)

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis
por: Mahal, Brandon A., et al.
Publicado: (2023)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses
por: Xie, Wanling, et al.
Publicado: (2019)

How do you design randomised trials for smaller populations? A framework
por: Parmar, Mahesh K. B., et al.
Publicado: (2016)

Giant osteoclasts in patients under bisphosphonates
por: Mac-Way, Fabrice, et al.
Publicado: (2014)

The role of bisphosphonates in breast cancer: Development of bisphosphonates
por: Fleisch, Herbert
Publicado: (2002)

Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study
por: Vale, Claire L, et al.
Publicado: (2015)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings
por: Noor, Nurulamin M., et al.
Publicado: (2020)

Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up
por: Guerin, Mathilde, et al.
Publicado: (2013)

Bisphosphonates for osteoarthritis
por: Walsh, David A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1vp6e8ji4ek4cob1os1jk7u4lu